Crop Biotech Update

Researchers Use CRISPR Technology to Treat Beta Thalassemia Patients

September 19, 2018

The first human trial in the U.S. using CRISPR gene-editing technology will soon be launched by Vertex Pharmaceuticals and CRISPR Therapeutics. The developers will conduct the trial to evaluate CTX001, a stem cell therapy developed using CRISPR to treat patients with beta thalassemia, a blood disorder characterized by low levels of hemoglobin which can lead to lack of oxygen in various parts of the body. The trial will be conducted at a German testing site.

Read more from Biocentury.